Clinical Trial Update: CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) [Phase 3]

View source ↗

Summary

Phase 3 CHESS trial evaluating CDK4/6 inhibitors added to standard adjuvant endocrine therapy for high-risk HR+/HER2+ early breast cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer, Adjuvant Therapy | Phase 3 | Status: RECRUITING